Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 4, 1996, Pages 1619-1622

  Romei, Cristina ^a,d   Elisei, Rossella ^a   Pinchera, Aldo ^a   Ceccherini, Isabella ^b   Molinaro, Eleonora ^a   Mancusi, Francesco ^a   Martino, Enio ^a   Romeo, Giovanni ^b   Pacini, Furio ^a,c  

^a UNIVERSITY OF PISA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c Istituto di Endocrinologia   (Italy)

^d Assoc Italiana la Ric sul Cancro

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; DNA;

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; HUMAN; HUMAN TISSUE; MALE; ONCOGENE RET; PARATHYROID ADENOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; TUMOR RECURRENCE;

ADULT; AGED; AMINO ACID SEQUENCE; BASE SEQUENCE; CALCITONIN; CARCINOMA, MEDULLARY; CYSTEINE; DNA; DNA PRIMERS; DNA, NEOPLASM; DROSOPHILA PROTEINS; EXONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; POINT MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES; RECURRENCE; RESTRICTION MAPPING; THYROID NEOPLASMS; TYROSINE;

EID: 0029986851     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.4.1619     Document Type: Article

References (14)

1. Mulligan LM, Kwok JBJ, Healey CS, et al. 1993 Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 363: 458-460.
2. Donis-Keller H, Dou S, Chi D, et al. 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet. 2:851-856.
3. Hofstra RMW, Landsvater RM, Ceccherini I, et al. 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 367:375-376.
4. Mulligan LM, Eng C, Healey CS, et al. 1994 Specific mutation of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet. 6:70-74.
5. 634-Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest. 17:201-204.
6. Zedenius J, Walljn G, Hamberger B, Nordenskjold M, Weber G, Larsson C. 1994 Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. Hum Mol Genet. 3:1259-1262.
7. Eng C, Smith DP, Mulligan LM, et al. 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 3:237-241.
8. Blaugrund JE, Johns MM, Eby YJ, et al. 1994 RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Hum Mol Genet. 3:1895-1897.
9. Ceccherini I, Hofstra R, Yin L, et al. 1994 DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene. 9:3025-3029.
10. McMahon R, Mulligan ML, Healey SC, et al. 1994 Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families. Hum Mol Genet. 3:643-646.
11. Pacini F, Martino E, Romei C, et al. 1994 Treatment of preclinical medullary thyroid carcinoma in MEN 2A gene carrier. Lancet 344:1084-105.
12. Lips CJM, Landsvater RM, Hoppener JWM, et al. 1994 Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 331:828-835.
13. Wells SA, Chi DD, Toshima K, et al. 1994 Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 220:237-250.
14. Carlson KM, Dou S, Chi D, et al. 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA. 91:1579-1583.